A call for reporting of tumor-specific outcomes in studies of DPYD genotyping.
作者信息
Ndayishimiye Jean De Dieu, Cayabyab Mari, Hoffecker Glenda, Wittner Victoria, Tuteja Sony
机构信息
Division of Translational Medicine and Human Genetics, Department of Medicine Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Department of Pharmacy, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
出版信息
Clin Transl Sci. 2024 Aug;17(8):e70003. doi: 10.1111/cts.70003.
Abstract
摘要
相似文献
1
A call for reporting of tumor-specific outcomes in studies of DPYD genotyping.
Clin Transl Sci. 2024 Aug;17(8):e70003. doi: 10.1111/cts.70003.
2
Reply to "A call for reporting of tumor-specific outcomes in studies of DPYD genotyping".
Clin Transl Sci. 2024 Aug;17(8):e70008. doi: 10.1111/cts.70008.
3
Impact of pretreatment dihydropyrimidine dehydrogenase genotype-guided fluoropyrimidine dosing on chemotherapy associated adverse events.
Clin Transl Sci. 2021 Jul;14(4):1338-1348. doi: 10.1111/cts.12981. Epub 2021 Feb 23.
4
Evaluation of clinical implementation of prospective DPYD genotyping in 5-fluorouracil- or capecitabine-treated patients.
Pharmacogenomics. 2016 May;17(7):721-9. doi: 10.2217/pgs-2016-0013. Epub 2016 May 16.
5
The Prevalence of DPYD*9A(c.85T>C) Genotype and the Genotype-Phenotype Correlation in Patients with Gastrointestinal Malignancies Treated With Fluoropyrimidines: Updated Analysis.
Clin Colorectal Cancer. 2019 Sep;18(3):e280-e286. doi: 10.1016/j.clcc.2019.04.005. Epub 2019 May 3.
6
Dihydropyrimidine Dehydrogenase Deficiency and Implementation of Upfront DPYD Genotyping.
Clin Pharmacol Ther. 2022 Oct;112(4):791-802. doi: 10.1002/cpt.2667. Epub 2022 Jun 12.
7
Metabolic rewiring is required for epithelial-mesenchymal transition.
Cancer Discov. 2014 Nov;4(11):OF20. doi: 10.1158/2159-8290.CD-RW2014-190. Epub 2014 Sep 11.
8
Addressing barriers to increased adoption of DPYD genotyping at a large multisite cancer center.
Am J Health Syst Pharm. 2023 Sep 22;80(19):1342-1349. doi: 10.1093/ajhp/zxad117.
9
Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among Caucasian and non-Caucasian patients with 5-FU- and capecitabine-related toxicity using full sequencing of DPYD.
Cancer Genomics Proteomics. 2013 Mar-Apr;10(2):89-92.
10
DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU: results from genotyping study on 75 gastric carcinoma and colon carcinoma patients.
Med Oncol. 2007;24(2):251-8. doi: 10.1007/BF02698048.
本文引用的文献
1
Evaluating the frequency and the impact of pharmacogenetic alleles in an ancestrally diverse Biobank population.
J Transl Med. 2022 Nov 28;20(1):550. doi: 10.1186/s12967-022-03745-5.
2
Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients.
Breast Cancer Res Treat. 2019 Jun;175(2):511-517. doi: 10.1007/s10549-019-05144-9. Epub 2019 Feb 12.
3
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
Lancet Oncol. 2018 Nov;19(11):1459-1467. doi: 10.1016/S1470-2045(18)30686-7. Epub 2018 Oct 19.
4
Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy.
Ann Oncol. 2003 Aug;14(8):1227-33. doi: 10.1093/annonc/mdg346.
Zotero 插件